Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8379840 | 0.93 | LMNA (0.39) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL17124727 | 0.88 | LMNA (0.41) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL8741511 | 0.87 | LMNA (0.39) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL3046708 | 0.86 | LMNA (0.39) | LMNACYP2C19HIF1A | |
| SCHEMBL12137493 | 0.86 | LMNA (0.36) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8377994 | 0.86 | LMNA (0.38) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL7594756 | 0.86 | LMNA (0.36) | LMNACYP2C19HIF1AABCB1 | |
| SCHEMBL8378374 | 0.85 | LMNA (0.34) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL7056140 | 0.85 | LMNA (0.46) | LMNACYP2C19HIF1AABCB1TDP1 | |
| SCHEMBL12871782 | 0.85 | LMNA (0.41) | LMNACYP2C19HIF1AABCB1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551449-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2013-10-08 | — | — | US | disclosed |
| US-20100260685-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-10-14 | — | — | US | disclosed |
| EP-2203190-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009056555-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100260685-A1 | CONTRAST AGENTS | ZYX, ZFX, UTS2R | LMNA 1353/4885CYP2C19 3407/4885HIF1A 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.